Progyny director Kevin Gordon sells $321,358 in company stock
Progyny director Kevin Gordon sold 11,500 shares of the company's stock on September 10, 2026, for $321,358. The average price per share was $27.9442, with individual sales occurring between $26.99 and $27.24. This follows a 59% increase in the stock price over six months. Despite Gordon's insider sale, the stock is considered undervalued by InvestingPro analysts, who gave Progyny a Fair Value score of 3.51 out of 5.
The sale followed an option exercise that allowed Gordon to purchase 22,000 shares at $13.00 each, totaling $286,000. An additional 10,500 shares were sold to cover tax and exercise costs, bringing Gordon's total ownership to 6,792 shares. Progyny reported strong Q2 2026 results, beating analyst expectations with $0.55 earnings per share on $350.51 million in revenue.
Despite a potential summer slowdown, the company kept its full-year revenue guidance between $1.36 billion and $1.385 billion. Citizens raised its price target to $33.00, citing the company's new partnerships and fixed premium offering.
Written by urgent.news from Investing.com's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
